Results 21 to 30 of about 30,293 (303)
Polyphenol-based targeted therapy for oral submucous fibrosis
InflammoPharmacology, 2023 Oral submucous fibrosis (OSF) is a chronic, progressive, and precancerous condition mainly caused by chewing areca nut. Currently, OSF therapy includes intralesional injection of corticosteroids with limited therapeutic success in disease management ...
C. Mehta +7 more
semanticscholar +1 more source
Drug treatment for oral submucous fibrosis: an update
BMC Oral Health, 2023 Objective The aim of this review is to evaluate the different medicinal interventions available for the management of oral submucous fibrosis (OSF).
Xueru Chen, Hui Xie, Jincai Guo
semanticscholar +1 more source
Drug-loaded mucoadhesive microneedle patch for the treatment of oral submucous fibrosis
Frontiers in Bioengineering and Biotechnology, 2023 Oral submucous fibrosis is a chronic, inflammatory and potentially malignant oral disease. Local delivery of triamcinolone to lesion site is a commonly used therapy.
Xian Cheng +7 more
semanticscholar +1 more source
Medicina Oral, 2023 Background Oral submucous fibrosis (OSF) and proliferative verrucous leukoplakia (PVL) are established as oral potentially malignant disorders. Dual pathology of the two conditions is not commonly encountered in clinical practice.
Vinay K. Hazarey +2 more
openalex +2 more sources
MiR-424/TGIF2-Mediated Pro-Fibrogenic Responses in Oral Submucous Fibrosis
International Journal of Molecular Sciences, 2023 Oral submucous fibrosis (OSF) has been recognized as a potentially malignant disorder and is characterized by inflammation and the deposition of collagen.
M. Chou +5 more
semanticscholar +1 more source
Journal of Contemporary Dentistry, 2016 Oral submucous fibrosis (OSF) is a chronic, insidious disease characterised by progressive submucosal fibrosis of the oral cavity and the oropharynx. The disease sometimes extends to the pharynx and upper third of the oesophagus. As the disease progresses, the resulting loss of fibroelasticity and stiffening of the oral mucosa leads to limitation in ...
Saman Warnakulasuriya +2 more
+4 more sources
International Journal of Molecular Sciences, 2023 The objective of the study was to compare the expression of immunohistochemical (IHC) markers of oral submucous fibrosis (OSMF) (non-transformed group) to those of oral squamous cell carcinoma (OSCC) transformed from OSMF (transformed group).
D. Mohapatra +5 more
semanticscholar +1 more source
Langerhans cell expression in oral submucous fibrosis: An immunohistochemical analysis
Journal of Oral and Maxillofacial Pathology, 2023 Introduction: Langerhans cells (LCs) are dendritic cells (DCs) of the epithelium which play a role in an array of oral lesions from gingivitis to oral cancer. Oral submucous fibrosis (OSMF), a potentially malignant disorder (PMD), is an insidious chronic
Shugufta Shafi +3 more
semanticscholar +1 more source
Cancers, 2023 Simple Summary Oral submucous fibrosis is a progressive oral disorder categorized as a potentially malignant condition. Researchers have identified specific molecular biomarkers associated with oral submucous fibrosis.
Jie-Ru You +10 more
semanticscholar +1 more source
Malignant Transformation Rate of Oral Submucous Fibrosis: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine, 2022 Oral submucous fibrosis (OSF) is a chronic progressive condition affecting the oral cavity, oropharynx and upper third of the oesophagus. It is a potentially malignant disorder.
V. Murthy +20 more
semanticscholar +1 more source